Literature DB >> 2872857

Sulphasalazine in ankylosing spondylitis.

N Feltelius, R Hällgren.   

Abstract

In recent years sulphasalazine has gained acceptance as an effective agent for the treatment of rheumatoid arthritis. Ankylosing spondylitis is a disease where remission inducing drugs so far have been lacking. In this double blind trial sulphasalazine was compared with placebo in 37 patients with ankylosing spondylitis. Evaluation after three months' treatment showed reduction of inflammatory activity and improvement of clinical variables. The side effects were mild. The results suggest that sulphasalazine is a potentially effective and safe drug in the treatment of ankylosing spondylitis.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2872857      PMCID： PMC1001898          DOI： 10.1136/ard.45.5.396

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  10 in total

1.  Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis.

Authors:  S C TRUELOVE; G WATKINSON; G DRAPER
Journal:  Br Med J       Date:  1962-12-29

2.  A biochemical assessment of sulphasalazine in rheumatoid arthritis.

Authors:  H A Bird; J S Dixon; M E Pickup; V M Rhind; J R Lowe; M R Lee; V Wright
Journal:  J Rheumatol       Date:  1982 Jan-Feb       Impact factor: 4.666

Review 3.  Reiter's syndrome and reactive arthritis in perspective.

Authors:  A Keat
Journal:  N Engl J Med       Date:  1983-12-29       Impact factor: 91.245

4.  "Postinfectious" arthritis. New look at an old concept with particular attention to disseminated gonococcal infection.

Authors:  D L Goldenberg
Journal:  Am J Med       Date:  1983-06       Impact factor: 4.965

5.  Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effects of sulfasalazine in vivo and in vitro.

Authors:  A Rubinstein; K M Das; J Melamed; R A Murphy
Journal:  Clin Exp Immunol       Date:  1978-08       Impact factor: 4.330

6.  The influence of salicyl-azo-sulfapyridine on the immune response to antigenic tumour cells inoculated into the coecal lumen of C3H mice.

Authors:  M L Laursen
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

7.  Inhibition of platelet thromboxane synthetase by sulfasalazine.

Authors:  W F Stenson; E Lobos
Journal:  Biochem Pharmacol       Date:  1983-07-15       Impact factor: 5.858

8.  Effects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle.

Authors:  J R Hoult; P K Moore
Journal:  Br J Pharmacol       Date:  1980-04       Impact factor: 8.739

9.  Sulphasalazine in rheumatoid arthritis.

Authors:  B McConkey; R S Amos; S Durham; P J Forster; S Hubball; L Walsh
Journal:  Br Med J       Date:  1980-02-16

10.  A sequential study of the relationship between faecal Klebsiella aerogenes and the common clinical manifestations of ankylosing spondylitis.

Authors:  C J Eastmond; M Calguner; R Shinebaum; E M Cooke; V Wright
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103
  10 in total
  20 in total

1.  Enumeration of IgA producing cells by the enzyme linked immunospot (ELISPOT) technique to evaluate sulphasalazine effects in inflammatory arthritides.

Authors:  N Feltelius; S Gudmundsson; L Wennersten; O Sjöberg; R Hällgren; L Klareskog
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

Review 2.  A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis.

Authors:  L Goh; A Samanta
Journal:  Rheumatol Int       Date:  2009-06-28       Impact factor: 2.631

3.  Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies.

Authors:  L Altomonte; A Zoli; A Veneziani; L Mirone; G Santacesaria; C Chiarelli; F Federico; G Massi; M Magaro
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

4.  Treatment of psoriatic arthritis with sulphasalazine: a one year open study.

Authors:  M Farr; G D Kitas; L Waterhouse; R Jubb; D Felix-Davies; P A Bacon
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

5.  Enhanced jejunal production of antibodies to Klebsiella and other Enterobacteria in patients with ankylosing spondylitis and rheumatoid arthritis.

Authors:  O Mäki-Ikola; R Hällgren; L Kanerud; N Feltelius; L Knutsson; K Granfors
Journal:  Ann Rheum Dis       Date:  1997-07       Impact factor: 19.103

6.  Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment.

Authors:  H G Taylor; E J Beswick; P T Dawes
Journal:  Clin Rheumatol       Date:  1991-03       Impact factor: 2.980

Review 7.  Current guidelines for the drug treatment of ankylosing spondylitis.

Authors:  E Toussirot; D Wendling
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

8.  Evaluation of sulphasalazine in the treatment of spondyloarthropathies.

Authors:  M Dougados; A Maetzel; M Mijiyawa; B Amor
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

9.  Ankylosing spondylitis. Current drug treatment.

Authors:  J T Gran; G Husby
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

10.  Raised circulating levels of the eosinophil cationic protein in ankylosing spondylitis: relation with the inflammatory activity and the influence of sulphasalazine treatment.

Authors:  N Feltelius; R Hällgren; P Venge
Journal:  Ann Rheum Dis       Date:  1987-05       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.